
Drs. Kydd and Sun on the state of MRD and ctDNA in GU and head and neck cancer, and where personalization is reshaping neoadjuvant and adjuvant decisions.

Drs. Kydd and Sun on the state of MRD and ctDNA in GU and head and neck cancer, and where personalization is reshaping neoadjuvant and adjuvant decisions.

How to tell a durable trend from hype, when a single-arm phase 2 is enough, and counseling patients on fast-moving pipelines in GU and head and neck cancer.

Setting realistic expectations around trials and biomarker testing — and the widening access gap, including drugs approved in Asia but unavailable in the US.